Virtual Symposium: Reducing Cardiovascular Risk (CME Concluded): A Paradigm Shift in T2DM Management

Although the association between type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) remains complex, there is a dire need for comprehensive strategies to reduce the risk of adverse CV events in patients with T2DM. In recent years, several antihyperglycemic agents have shown that they not only improve glycemic parameters, but also reduce the risk of cardiovascular events, as demonstrated in multiple cardiovascular outcome trials (CVOT). These trials, originally designed to demonstrate CV safety, have provided valuable practice-changing insights that have shifted the focus of T2DM care beyond glucose control into CV risk management and prevention.

Cardiovascular Disease Comorbidities in Type II Diabetes

Presenter: Tracy Wang, MD, MHS, MSc

Review of Results of Recent CVOTs

Presenter: Lawrence Blonde, MD

What Have We Learned from Trials and Individualization of Therapy

Chairperson: Robert H. Eckel, MD

Case Presentation and Discussion

Presenter: Tracy Wang, MD, MHS, MSc

Panel: All Faculty